Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer

Sun Young Kong, Mi Hwa Han, Heon Jong Yoo, Jong Ha Hwang, Myong Cheol Lim, Sang Soo Seo, Chong Woo Yoo, Jae-Hoon Kim, Sang Yoon Park, Sokbom Kang

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background. This study was designed to determine whether serum HE4 is an independent prognostic factor in ovarian cancer patients. Methods. We measured HE4 in pretreatment serum samples from 80 women with epithelial ovarian cancer, using an enzyme-linked immunosorbent assay. The results were correlated with clinical data. Results. The median serum HE4 level in ovarian cancer patients was 98.7 (range, 80.3-222.8) pg/ml. Elevated serum HE4 levels before therapy significantly correlated with a poorer progression free survival (log-rank test, P = 0.017). Multivariate analysis revealed serum HE4 to be an independent prognostic factor for progression-free survival (P = 0.036). In multivariate regression analysis, high serum HE4 levels significantly correlated with high tumor grade and serous histology (P = 0.004 and 0.017). In addition, high serum HE4 levels were significantly associated with residual tumor size and operative time (P = 0.003 and 0.033). Conclusions. Pretreatment serum HE4 seems to be an additional factor for predicting the outcome of patients with epithelial ovarian cancer. Due to its independence from established prognostic factors, serum HE4 may provide additional prognostic information.

Original languageEnglish
Pages (from-to)1707-1712
Number of pages6
JournalAnnals of Surgical Oncology
Volume19
Issue number5
DOIs
Publication statusPublished - 2012 May 1

Fingerprint

Serum
Ovarian Neoplasms
Disease-Free Survival
Multivariate Analysis
Ovarian epithelial cancer
Residual Neoplasm
Operative Time
Histology
Enzyme-Linked Immunosorbent Assay
Regression Analysis
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Kong, S. Y., Han, M. H., Yoo, H. J., Hwang, J. H., Lim, M. C., Seo, S. S., ... Kang, S. (2012). Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer. Annals of Surgical Oncology, 19(5), 1707-1712. https://doi.org/10.1245/s10434-011-1943-5
Kong, Sun Young ; Han, Mi Hwa ; Yoo, Heon Jong ; Hwang, Jong Ha ; Lim, Myong Cheol ; Seo, Sang Soo ; Yoo, Chong Woo ; Kim, Jae-Hoon ; Park, Sang Yoon ; Kang, Sokbom. / Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer. In: Annals of Surgical Oncology. 2012 ; Vol. 19, No. 5. pp. 1707-1712.
@article{2a073a2c8cdc4b88af2049f877a53230,
title = "Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer",
abstract = "Background. This study was designed to determine whether serum HE4 is an independent prognostic factor in ovarian cancer patients. Methods. We measured HE4 in pretreatment serum samples from 80 women with epithelial ovarian cancer, using an enzyme-linked immunosorbent assay. The results were correlated with clinical data. Results. The median serum HE4 level in ovarian cancer patients was 98.7 (range, 80.3-222.8) pg/ml. Elevated serum HE4 levels before therapy significantly correlated with a poorer progression free survival (log-rank test, P = 0.017). Multivariate analysis revealed serum HE4 to be an independent prognostic factor for progression-free survival (P = 0.036). In multivariate regression analysis, high serum HE4 levels significantly correlated with high tumor grade and serous histology (P = 0.004 and 0.017). In addition, high serum HE4 levels were significantly associated with residual tumor size and operative time (P = 0.003 and 0.033). Conclusions. Pretreatment serum HE4 seems to be an additional factor for predicting the outcome of patients with epithelial ovarian cancer. Due to its independence from established prognostic factors, serum HE4 may provide additional prognostic information.",
author = "Kong, {Sun Young} and Han, {Mi Hwa} and Yoo, {Heon Jong} and Hwang, {Jong Ha} and Lim, {Myong Cheol} and Seo, {Sang Soo} and Yoo, {Chong Woo} and Jae-Hoon Kim and Park, {Sang Yoon} and Sokbom Kang",
year = "2012",
month = "5",
day = "1",
doi = "10.1245/s10434-011-1943-5",
language = "English",
volume = "19",
pages = "1707--1712",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "5",

}

Kong, SY, Han, MH, Yoo, HJ, Hwang, JH, Lim, MC, Seo, SS, Yoo, CW, Kim, J-H, Park, SY & Kang, S 2012, 'Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer', Annals of Surgical Oncology, vol. 19, no. 5, pp. 1707-1712. https://doi.org/10.1245/s10434-011-1943-5

Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer. / Kong, Sun Young; Han, Mi Hwa; Yoo, Heon Jong; Hwang, Jong Ha; Lim, Myong Cheol; Seo, Sang Soo; Yoo, Chong Woo; Kim, Jae-Hoon; Park, Sang Yoon; Kang, Sokbom.

In: Annals of Surgical Oncology, Vol. 19, No. 5, 01.05.2012, p. 1707-1712.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer

AU - Kong, Sun Young

AU - Han, Mi Hwa

AU - Yoo, Heon Jong

AU - Hwang, Jong Ha

AU - Lim, Myong Cheol

AU - Seo, Sang Soo

AU - Yoo, Chong Woo

AU - Kim, Jae-Hoon

AU - Park, Sang Yoon

AU - Kang, Sokbom

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Background. This study was designed to determine whether serum HE4 is an independent prognostic factor in ovarian cancer patients. Methods. We measured HE4 in pretreatment serum samples from 80 women with epithelial ovarian cancer, using an enzyme-linked immunosorbent assay. The results were correlated with clinical data. Results. The median serum HE4 level in ovarian cancer patients was 98.7 (range, 80.3-222.8) pg/ml. Elevated serum HE4 levels before therapy significantly correlated with a poorer progression free survival (log-rank test, P = 0.017). Multivariate analysis revealed serum HE4 to be an independent prognostic factor for progression-free survival (P = 0.036). In multivariate regression analysis, high serum HE4 levels significantly correlated with high tumor grade and serous histology (P = 0.004 and 0.017). In addition, high serum HE4 levels were significantly associated with residual tumor size and operative time (P = 0.003 and 0.033). Conclusions. Pretreatment serum HE4 seems to be an additional factor for predicting the outcome of patients with epithelial ovarian cancer. Due to its independence from established prognostic factors, serum HE4 may provide additional prognostic information.

AB - Background. This study was designed to determine whether serum HE4 is an independent prognostic factor in ovarian cancer patients. Methods. We measured HE4 in pretreatment serum samples from 80 women with epithelial ovarian cancer, using an enzyme-linked immunosorbent assay. The results were correlated with clinical data. Results. The median serum HE4 level in ovarian cancer patients was 98.7 (range, 80.3-222.8) pg/ml. Elevated serum HE4 levels before therapy significantly correlated with a poorer progression free survival (log-rank test, P = 0.017). Multivariate analysis revealed serum HE4 to be an independent prognostic factor for progression-free survival (P = 0.036). In multivariate regression analysis, high serum HE4 levels significantly correlated with high tumor grade and serous histology (P = 0.004 and 0.017). In addition, high serum HE4 levels were significantly associated with residual tumor size and operative time (P = 0.003 and 0.033). Conclusions. Pretreatment serum HE4 seems to be an additional factor for predicting the outcome of patients with epithelial ovarian cancer. Due to its independence from established prognostic factors, serum HE4 may provide additional prognostic information.

UR - http://www.scopus.com/inward/record.url?scp=84862558119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862558119&partnerID=8YFLogxK

U2 - 10.1245/s10434-011-1943-5

DO - 10.1245/s10434-011-1943-5

M3 - Article

VL - 19

SP - 1707

EP - 1712

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 5

ER -